GSK’s (GSK) Equal Weight Rating Reaffirmed at Barclays

Barclays restated their equal weight rating on shares of GSK (LON:GSK) in a report released on Tuesday, Marketbeat Ratings reports. They currently have a GBX 1,725 ($21.67) price target on the stock.

GSK has been the subject of several other research reports. Berenberg Bank lifted their price objective on GSK from GBX 1,650 ($20.73) to GBX 1,820 ($22.86) and gave the stock a buy rating in a report on Wednesday, February 14th. Shore Capital reiterated a buy rating on shares of GSK in a research report on Wednesday, May 1st. Deutsche Bank Aktiengesellschaft reiterated a buy rating and set a GBX 1,950 ($24.50) target price on shares of GSK in a research report on Wednesday, April 17th. Finally, JPMorgan Chase & Co. lifted their target price on GSK from GBX 1,530 ($19.22) to GBX 1,660 ($20.85) and gave the company an underweight rating in a research report on Thursday, May 2nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of Hold and an average target price of GBX 1,675.63 ($21.05).

GSK Stock Performance

Shares of GSK opened at GBX 1,771 ($22.25) on Tuesday. The company has a debt-to-equity ratio of 140.82, a current ratio of 0.88 and a quick ratio of 0.73. GSK has a one year low of GBX 1,302.60 ($16.36) and a one year high of GBX 1,772.50 ($22.27). The firm has a market capitalization of £72.43 billion, a P/E ratio of 1,468.79, a PEG ratio of 1.12 and a beta of 0.27. The business has a fifty day moving average of GBX 1,666.29 and a 200 day moving average of GBX 1,562.88.

GSK Cuts Dividend

The firm also recently disclosed a dividend, which will be paid on Thursday, July 11th. Stockholders of record on Thursday, May 16th will be given a GBX 15 ($0.19) dividend. The ex-dividend date is Thursday, May 16th. This represents a dividend yield of 0.9%. GSK’s payout ratio is 5,333.33%.

Insider Activity

In other GSK news, insider Urs Rohner acquired 434 shares of the stock in a transaction dated Wednesday, March 20th. The shares were acquired at an average cost of GBX 1,662 ($20.88) per share, for a total transaction of £7,213.08 ($9,061.66). In other news, insider Emma Walmsley sold 139,792 shares of GSK stock in a transaction dated Friday, February 16th. The stock was sold at an average price of GBX 1,658 ($20.83), for a total value of £2,317,751.36 ($2,911,747.94). Also, insider Urs Rohner bought 434 shares of GSK stock in a transaction dated Wednesday, March 20th. The stock was purchased at an average cost of GBX 1,662 ($20.88) per share, for a total transaction of £7,213.08 ($9,061.66). Company insiders own 1.77% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.